Single-cell RNA sequencing of T3 sarcoma tumors following treatment with CD8-mIL2, CTRL-not-alpha-mIL2, or anti-PD-1
CD8+ TILs from T3 sarcomas were analyzed using single-cell RNA-sequencing (scRNA-seq) 2 or 4 days after therapy with CD8-mIL2, CTRL-not-alpha-mIL2, anti-PD-1, or combinations thereof. Barcoded peptide:MHC reagents (BEAM, 10X Genomics) were included to identify mLama4-specific CD8+ T cells.